Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD

NCT02680197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

262

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: CHF5259 or Placebo administration

Sponsor

Chiesi Farmaceutici S.p.A.